Drug Trial Radar · NCT04637529
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
Aug 5, 2022
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Apsen Farmaceutica S.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an active treatment for pain control in individuals diagnosed with osteoarthritis.
Conditions
- Osteoarthritis
Interventions
S (+) - IbuprofenDrug
S (+) - Ibuprofen + placebo of Ibuvix®
Ibuvix® - ibuprofenDrug
Ibuvix® + placebo of S(+) - Ibuprofen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean reduction of pain measured by the WOMAC Osteoarthritis Index (pain)Time frame: Baseline (day 0) and Week 4 (day 28)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Apsen Farmacêutica S.A.
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.